Nightstar Therapeutics

21 articles about Nightstar Therapeutics

• 

  Biogen and Samsung Bioepis Heat Up the Lucrative AMD Market with First Biosim...

  9/20/2021

  Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market. 
• 

  Massachusetts Life Science M&A Hits $22.5 Billion So Far This Year

  7/10/2019

  As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
• 

  Biogen Banks on Ophthalmology Gene Therapies With $800 Million Acquisition of Nightstar

  3/4/2019

  For Biogen, the acquisition brings Nightstar’s lead asset, NSR-REP1, a treatment for treatment of choroideremia (CHM), a rare and degenerative, X-linked inherited retinal disorder that leads to blindness, into its pipeline.

• BIOGEN ANNOUNCES AGREEMENT TO ACQUIRE NIGHTSTAR THERAPEUTICS TO ESTABLISH CLINICAL PIPELINE OF GENE THERAPY CANDIDATES IN OPHTHALMOLOGY

  3/4/2019

  Biogen (Nasdaq: BIIB) today announced that it has entered into an agreement to acquire Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company based in London, United Kingdom, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders

• Nightstar Therapeutics to Present at 2018 Chardan Genetic Medicines Conference

  10/4/2018

  Nightstar Therapeutics plc today announced that the company plans on presenting at the Chardan Genetic Medicines Conference, on Tuesday October 9, 2018 at 2:45 p.m. ET in New York City.

• Nightstar Announces Closing of Public Offering and Full Exercise of Underwriters’ Option

  10/2/2018

  Nightstar Therapeutics plc today announced the closing of its underwritten public offering of 4,600,000 American Depositary Shares (“ADSs”) representing 4,600,000 ordinary shares, at a public offering price of $18.00 per ADS, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 ADSs.

• Nightstar Reports Positive Proof of Concept Data from Dose Escalation Study in XIRIUS Trial for NSR-RPGR in XLRP Patients

  9/24/2018

  Nightstar Therapeutics plc, announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress.

• Bascom Palmer Treats First U.S. Patient in Nightstar Gene Therapy Clinical Trial for X-Linked Retinitis Pigmentosa

  9/19/2018

  A Puerto Rican patient with X-linked retinitis pigmentosa is hoping to save his vision after an innovative gene therapy procedure at Bascom Palmer Eye Institute.

• Nightstar Expands Pipeline With Novel Gene Therapy for the Treatment of Stargardt Disease

  11/8/2017

  Stargardt disease is the most common form of inherited juvenile macular dystrophy with a prevalence of one in 10,000.

• NightstaRx Appoints Tuyen Ong As Chief Development Officer

  8/2/2017

• NightstaRx Appoints David Lubner To Its Board Of Directors

  7/17/2017

• Nightstar Raises $45 Million To Fund Development Of Gene Therapies For Blinding Retinal Diseases

  6/30/2017

• Eye Gene Therapy Firm NightstaRx Nabs Another $45 Million

  6/30/2017

• NightstaRx Appoints Ophthalmology Industry Veteran Scott Whitcup To Board Of Directors

  5/2/2017

• NightstaRx Appoints Healthcare Finance Leader Senthil Sundaram As Chief Financial Officer

  4/4/2017

• NightstaRx Commences First Phase I/II Gene Therapy Clinical Trial For Patients With X-Linked Retinitis Pigmentosa

  3/20/2017

• NightstaRx Expands Leadership Team, Names Gregory Robinson, Ph.D., As Chief Scientific Officer

  9/13/2016

• NightstaRx Reports Long-Term Benefits Of Gene Therapy For Inherited Form Of Progressive Blindness, As Published In The New England Journal Of Medicine

  4/29/2016

• NightstaRx Announces The Start Of A Miami Gene Therapy Study To Treat Choroideremia

  11/12/2015

• NightstaRx And University of Alberta Announce The Start Of The First Canadian Gene Therapy Study To Treat Choroideremia

  6/29/2015